Trial Profile
Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DELAY
- 06 Jul 2012 Status changed from active, no longer recruiting to completed, based on results presented at ADA.
- 12 Jun 2012 Final results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2012 Primary endpoint 'C-peptide-levels' has been met.